Jian Chen1, Bing-Chan Wang, Jin-Hai Tang. 1. Department of General Surgery, The First Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, China.
Abstract
BACKGROUND: The aim of this study is to investigate clinical significance of miR-155 expression in breast cancer. METHODS: TaqMan real-time RT-PCR was performed to detect miR-155 expression in breast cancer tissues. The correlation of miR-155 expression with clinicopathological factors and prognosis of breast cancer patients was analyzed. Then, the prognostic value of miR-155 expression was analyzed by univariate and multivariate analyses. Moreover, the effect of miR-155 expression on phenotypes of breast cancer cell was determined by antisense technology. RESULTS: The relative expression of miR-155 was significantly higher in breast cancer tissues than in corresponding nontumor tissues. High miR-155 expression was correlated with higher tumor grade, advanced tumor stage and lymph node metastasis (P = 0.012, 0.001, and 0.003, respectively). Kaplan-Meier survival analysis indicated that the disease-free and overall survival rates of high miR-155 group were significantly lower than those of low miR-155 group (P = 0.038 and 0.029, respectively). Multivariate analysis showed that high miR-155 expression was a poor prognostic factor (P = 0.009). Furthermore, antisense targeting miR-155 could inhibit growth, induce cell arrest in G(0) /G(1) phase, enhance apoptosis, and increase radiosensitivity in breast cancer cells. CONCLUSIONS: MiR-155 expression might be an independent prognostic factor and a therapeutic target for human breast cancer.
BACKGROUND: The aim of this study is to investigate clinical significance of miR-155 expression in breast cancer. METHODS: TaqMan real-time RT-PCR was performed to detect miR-155 expression in breast cancer tissues. The correlation of miR-155 expression with clinicopathological factors and prognosis of breast cancerpatients was analyzed. Then, the prognostic value of miR-155 expression was analyzed by univariate and multivariate analyses. Moreover, the effect of miR-155 expression on phenotypes of breast cancer cell was determined by antisense technology. RESULTS: The relative expression of miR-155 was significantly higher in breast cancer tissues than in corresponding nontumor tissues. High miR-155 expression was correlated with higher tumor grade, advanced tumor stage and lymph node metastasis (P = 0.012, 0.001, and 0.003, respectively). Kaplan-Meier survival analysis indicated that the disease-free and overall survival rates of high miR-155 group were significantly lower than those of low miR-155 group (P = 0.038 and 0.029, respectively). Multivariate analysis showed that high miR-155 expression was a poor prognostic factor (P = 0.009). Furthermore, antisense targeting miR-155 could inhibit growth, induce cell arrest in G(0) /G(1) phase, enhance apoptosis, and increase radiosensitivity in breast cancer cells. CONCLUSIONS:MiR-155 expression might be an independent prognostic factor and a therapeutic target for humanbreast cancer.
Authors: Cornelia Lerner; Silke Wemmert; Florian Bochen; Philipp Kulas; Maximilian Linxweiler; Andrea Hasenfus; Joana Heinzelmann; Petra Leidinger; Christina Backes; Eckart Meese; Steffi Urbschat; Bernhard Schick Journal: J Cancer Res Clin Oncol Date: 2015-11-30 Impact factor: 4.553
Authors: Katrien Van Roosbroeck; Francesca Fanini; Tetsuro Setoyama; Cristina Ivan; Cristian Rodriguez-Aguayo; Enrique Fuentes-Mattei; Lianchun Xiao; Ivan Vannini; Roxana S Redis; Lucilla D'Abundo; Xinna Zhang; Milena S Nicoloso; Simona Rossi; Vianey Gonzalez-Villasana; Rajesha Rupaimoole; Manuela Ferracin; Fortunato Morabito; Antonino Neri; Peter P Ruvolo; Vivian R Ruvolo; Chad V Pecot; Dino Amadori; Lynne Abruzzo; Steliana Calin; Xuemei Wang; M James You; Alessandra Ferrajoli; Robert Orlowski; William Plunkett; Tara M Lichtenberg; Ramana V Davuluri; Ioana Berindan-Neagoe; Massimo Negrini; Ignacio I Wistuba; Hagop M Kantarjian; Anil K Sood; Gabriel Lopez-Berestein; Michael J Keating; Muller Fabbri; George A Calin Journal: Clin Cancer Res Date: 2016-11-30 Impact factor: 12.531